UNITED STATES JUDICIAL PANEL

MULTIDISTRICT LITIGATION

CHAIRMAN: Judge John G. Heyburn II United States District Court Western District of Kentucky

MEMBERS: Judge D. Lowell Jensen United States District Court Northern District of California

Judge J. Frederick Motz United States District Court District of Maryland

Judge Robert L. Miller, Jr. United States District Court Northern District of Indiana

Judge Kathryn H. Vratil United States District Court District of Kansas

Judge David R. Hansen United States Court of Appeals Eighth Circuit

Judge Anthony J. Scirica United States Court of Appeals Third Circuit

DIRECT REPLY TO:

Jeffery N. Lüthi Clerk of the Panel One Columbus Circle, NE Thurgood Marshall Federal Judiciary Building Room G-255, North Lobby Washington, D.C. 20002

Telephone: [202] 502-2800 Fax: [202] 502-2888 http://www.jpml.uscourts.gov

August 6, 2007

TO CLERKS OF THE FOLLOWING U. S. DISTRICT COURTS:

NORTHERN DISTRICT OF CALIFORNIA DISTRICT OF NEW JERSEY

MDL-1856 -- IN RE Depo-Provera Products Liability Litigation

(See Attached Schedule A of Order)

Dear Clerks:

I am enclosing a certified copy of an order filed today by the Panel in the above matter.

Very truly,

Jeffery N. Lithi

Clerk of the Panel

Mecca S. Khompson

Deputy Clerk

Enclosure

cc: Transferor Judges: Judge Saundra Brown Armstrong Judge Mary Little Cooper

100878-SBA Document 37 Filed 08/06/07 Page 2 of 4

A CERTIFIED TRUE COPY

ME JUDICIAL PA

ULTIDISTRICT LIDIGATION

AUG 7 6 2007

JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

AUG - 6 2007

UNITED STATES JUDICIAL PANEL
on
MULTIDISTRICT LITIGATION

FILED CLERK'S OFFICE

IN/RE: DEPO-PROVERA PRODUCTS LIABILITY LITIGATION

MDL No. 1856

ORDER DENYING TRANSFER

Before the entire Panel*: Plaintiffs in the Northern District of California actions have moved, pursuant to 28 U.S.C. § 1407, for coordinated or consolidated pretrial proceedings of this litigation in the District of New Jersey. This litigation currently consists of three actions listed on Schedule A, two actions in the Northern District of California and one action in the District of New Jersey. Defendants oppose centralization, but if the Panel deems centralization to be appropriate, support the selection of the District of New Jersey as transferee district.

On the basis of the papers filed and hearing session held, we are not persuaded that Section 1407 centralization would serve the convenience of the parties and witnesses or further the just and efficient conduct of this litigation. This motion involves only three actions. One action is a medical monitoring putative class action, while the other two actions are personal injury actions, which have already been consolidated before one judge in the Northern District of California. The proponents of centralization have failed to convince us that any common questions of fact among these three actions are sufficiently complex and/or numerous to justify Section 1407 transfer at this time. Alternatives to transfer exist that may be able to minimize whatever possibilities there might be of duplicative discovery and/or inconsistent pretrial rulings. See, e.g., In re Eli Lilly and Company (Cephalexin Monohydrate) Patent Litigation, 446 F.Supp. 242, 244 (J.P.M.L. 1978); see also Manual for Complex Litigation, Fourth, § 20.14 (2004).

IT IS THEREFORE ORDERED that the motion, pursuant to 28 U.S.C. § 1407, for centralization of these three actions is denied.

^{*} Judge Scirica did not participate in the decision of this matter.

¹ The Panel also has been notified that at least seven other related actions have been filed in multiple districts.

-2-

PANEL ON MULTIDISTRICT LITIGATION

John G. Heyburn II Chairman

D. Lowell Jensen Robert L. Miller, Jr. David R. Hansen J. Frederick Motz Kathryn H. Vratil Anthony J. Scirica*

IN RE: DEPO-PROVERA PRODUCTS LIABILITY LITIGATION

MDL No. 1856

SCHEDULE A

Northern District of California

Cindy Winward v. Pfizer Inc., et al., C.A. No. 4:07-878 Kimberly Cable v. Pfizer Inc., et al., C.A. No. 4:07-879

District of New Jersey

Priscilla D. Riddell, et al. v. Pfizer Inc., et al., C.A. No. 3:06-5418